Figure 1.
![Clinical events in extended thromboprophylaxis trials investigating both symptomatic and asymptomatic VTE. ADOPT, Apixaban Dosing to Optimize Protection from Thrombosis; APEX, The Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban; EXCLAIM, Extended Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients with Prolonged Immobilization trial; MAGELLAN, Venous Thromboembolic Event [VTE] Prophylaxis in Medically Ill Patients.](https://ash.silverchair-cdn.com/ash/content_public/journal/hematology/2019/1/10.1182_hematology.2019000026/5/hem2019000026cf1.png?Expires=1736063125&Signature=SY4kN0V~3adK6NGtKPyFFwhiVpl0MlK6ZlmbJK7OFb3CdtET6d74DB8BWkpdR7lt74wmu~i9BCMIz6zTNOc5r2BJpV5nCHWaBtDaO6df50S92LlB16v9QBfbW0lY63~htQqsR22JCOfkaMZpYzZ0s~oY5rcJi-v8aE4jzi1FS6W87UrgRqimJF5dLi5lf7O2YpcDQ~9heBP5-vVDrjKhdWwlChXim0zNY1u6T-m38sw0RpRlbAa-RoACSAYztPRaUYKt7b72t2hB415KYEBRbfQj1MWDe6TesiBmi0rigMH0dEEOabr-b65p0ZpXA0EhZHg-sNPqHvnKmLXj6r1xSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Clinical events in extended thromboprophylaxis trials investigating both symptomatic and asymptomatic VTE. ADOPT, Apixaban Dosing to Optimize Protection from Thrombosis; APEX, The Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban; EXCLAIM, Extended Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients with Prolonged Immobilization trial; MAGELLAN, Venous Thromboembolic Event [VTE] Prophylaxis in Medically Ill Patients.